This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy (HYPER)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2011 by University Hospital Birmingham.
Recruitment status was:  Recruiting
Sponsor:
Collaborators:
University of Birmingham
Brighton and Sussex University Hospitals NHS Trust
British Heart Foundation
Information provided by:
University Hospital Birmingham
ClinicalTrials.gov Identifier:
NCT00989508
First received: October 2, 2009
Last updated: August 10, 2011
Last verified: April 2011
October 2, 2009
August 10, 2011
October 2009
September 2012   (Final data collection date for primary outcome measure)
Absolute difference in Cardiac Index (>0.3 l/min/m2) [ Time Frame: 6 hours post-removal of aortic X-clamp ]
Same as current
Complete list of historical versions of study NCT00989508 on ClinicalTrials.gov Archive Site
  • Incidence of Low Cardiac Output Syndrome [ Time Frame: 6 hours post-removal of aortic X-clamp ]
  • Incidence of inotrope use according to protocol [ Time Frame: 6 and 12 hours post-removal of aortic X-clamp ]
  • Peak and total release of Troponin [ Time Frame: 12 and 24 hours post-release of aortic X-clamp ]
Same as current
Not Provided
Not Provided
 
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy
Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy

Open-heart surgery causes injury of the heart muscle. Although this is usually mild, temporary and reversible, if it is severe it can endanger life and require additional high cost care. During surgery, techniques are used to protect the heart from injury, but these remain imperfect. Patients with a thickened wall of the heart (left ventricular hypertrophy) may be at greater risk. This study assesses the effect of facilitating sugar metabolism (a more efficient fuel) by the heart muscle using the drug Perhexiline given before the operation.

This treatment has a sound experimental basis for improving outcome. If this improvement is confirmed surgical results could be improved. The investigators will be studying heart function, heart muscle energy stores and chemicals which quantify the amount of heart muscle injury. The investigators' hypothesis is that Perhexiline will improve the protection of the heart by decreasing damage that may occur during heart surgery.

Not Provided
Interventional
Phase 2
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Myocardial Reperfusion Injury
  • Cardiac Output, Low
  • Hypertrophy, Left Ventricular
  • Drug: Perhexiline
    Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
    Other Name: PEXSIG
  • Drug: Placebo marked PEXSIG
    Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
  • Experimental: Perhexiline
    Pre-operative administration of Perhexiline tablets according to dosing schedule
    Intervention: Drug: Perhexiline
  • Placebo Comparator: Placebo marked PEXSIG
    Pre-operative administration of placebo tablets according to dosing schedule
    Intervention: Drug: Placebo marked PEXSIG

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
220
December 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult
  • First-time
  • Aortic valve surgery for aortic stenosis +/- coronary artery bypass

Exclusion Criteria:

  • Diabetes Mellitus
  • Renal impairment with Creatinine greater than or equal to 200micromol/L
  • Atrial fibrillation
  • Amiodarone therapy, recent (in last month) or current
  • Hepatic impairment, significant preoperative
  • Peripheral neuropathy
  • Pregnancy or breast-feeding
  • Emergency surgery or required on clinical grounds within 5 days of referral
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00989508
RRK3535
Eudract 2008-002376-95
REC 08/H0304/48
BHF PG/08/040
Yes
Not Provided
Not Provided
Mr Domenico Pagano, University Hospital Birmingham
University Hospital Birmingham
  • University of Birmingham
  • Brighton and Sussex University Hospitals NHS Trust
  • British Heart Foundation
Principal Investigator: Domeinco Pagano, MD FRCS University Hospital Birmingham
University Hospital Birmingham
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP